Tenders in Pharmaceutical products

Медицински санитетски материјал - алергени - УКЦК

УНИВЕРЗИТЕТСКИ КЛИНИЧКИ ЦЕНТАР КРАГУЈЕВАЦ, КРАГУЈЕВАЦ, ПИБ: 101042141

Лекови, санитетски и лабараториски материјал 2

ДОМ ЗА СМЕШТАЈ ОДРАСЛИХ ЛИЦА "КУЛИНА" АЛЕКСИНАЦ, Кулина, ПИБ: 100313224

Лекови ван Листе лекова – 2/4 (Радиофармацеутици – 4 и Антимон-сулфид – 3)

"ИНСТИТУТ ЗА ОНКОЛОГИЈУ ВОЈВОДИНЕ", СРЕМСКА КАМЕНИЦА, ПИБ: 100804613

Набавка регистрованих лекова ван Листе лекова за потребе Универзитетског клиничког центра Војводине

УНИВЕРЗИТЕТСКИ КЛИНИЧКИ ЦЕНТАР ВОЈВОДИНЕ, НОВИ САД, ПИБ: 101696893

Nabava nirsevimaba za seroprofilaksu respiratornog sincicijskog virusa (RSV)

Opća bolnica Pula - Ospedale Generale di Pola, Pula - Pola

Nabava klesrovimaba za seroprofilaksu respiratornog sincicijskog virusa (RSV)

Opća bolnica Pula - Ospedale Generale di Pola, Pula - Pola

National Generic Pharmaceuticals – Project Revive

NHS England

National Generic Pharmaceuticals – Project Revive DCE/DSW regions – 01/04/27 to 31/01/29 (22 months) DLS/DNE regions – 01/04/27 to 31/01/29 (22 months) DLN/DNW regions – 01/04/27 to 31/01/29 (22 months)

NHS National Framework for Macitentan tablets

NHS England

Project title: NHS National Framework Agreement for Macitentan & Cladribine Tablets Offer reference number: CM/TNS/26/5748 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5748/01 Macitentan Lot 1 DCE/DLN: 01/10/2027 to 30/09/2029 (24 months) CELN Lot 2 DNW/DLS: 01/10/2027 to 31/01/2029 (16 months) NWLS Lot 3 DNE/DSW: 01/10/2027 to 30/09/2029 (24 months) NESW CM/TNS/26/5748/02 Cladribine Tablets Lot 1 DCE/DSW: 01/10/2027 to 30/09/2029 (24 months) CESW Lot 2 DLN/DNW: 01/10/2027 to 31/01/2029 (16 months) NWLN Lot 3 DLS/DNE: 01/10/2027 to 30/09/2028 (12 months) LSNE Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

NHS National Framework Agreement for Macitentan & Cladribine Tablets

NHS England

Project title: NHS National Framework Agreement for Macitentan & Cladribine Tablets Offer reference number: CM/TNS/26/5748 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5748/01 Macitentan Lot 1 DCE/DLN: 01/10/2027 to 30/09/2029 (24 months) CELN Lot 2 DNW/DLS: 01/10/2027 to 31/01/2029 (16 months) NWLS Lot 3 DNE/DSW: 01/10/2027 to 30/09/2029 (24 months) NESW CM/TNS/26/5748/02 Cladribine Tablets Lot 1 DCE/DSW: 01/10/2027 to 30/09/2029 (24 months) CESW Lot 2 DLN/DNW: 01/10/2027 to 31/01/2029 (16 months) NWLN Lot 3 DLS/DNE: 01/10/2027 to 30/09/2028 (12 months) LSNE Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Лијекови са Листе лијекова који се примјењују у болничкој здравственој заштити

FOND ZDRAVSTVENOG OSIGURANJA REPUBLIKE SRPSKE

Набавка специфичних лијекова

FOND ZDRAVSTVENOG OSIGURANJA REPUBLIKE SRPSKE

Lijekovi za 2027.g

Županijska specijalna bolnica Insula, Rab

Набавка лекова за потребе неосигураних пацијената

ДОМ ЗДРАВЉА "ДР СИМО МИЛОШЕВИЋ", БЕОГРАД, ПИБ: 100974050

Lijekovi (ponovljeni postupak)

ZAVOD ZA HITNU MEDICINU SPLITSKO-DALMATINSKE ŽUPANIJE, Split

Lijekovi sa bolničke liste lijekova

ZU KANTONALNA BOLNICA "DR. IRFAN LJUBIJANKIĆ" BIHAĆ

LSL/MED/0254 The Supply and Manufacture of Unlicensed Medicines

LEIDOS SUPPLY, LIMITED

In April 2015 the MOD signed a thirteen year contract with Leidos Europe Ltd to provide the procurement and inventory management of commodity items (as well as the storage and distribution services) historically provided in-house by the Logistic Commodities and Services Operating Centre. Leidos, working with the MOD, will transform the way these services are delivered to ensure requirements continue to be met whilst providing best value for money for the department. The organisation delivering these services is known as Team Leidos. Team Leidos would like to make markets aware that we are intending to investigate innovative approaches to fill our Supply and Manufacture of Unlicensed Medicines requirements. It is the aim of this Preliminary Market Engagement Notice (PMEN) to encourage companies, suppliers, or manufacturers to make us aware and provide as much information as they are comfortable with, to help decide the future strategy for the range. Team Leidos wishes to generate interest, information and views with other companies to understand the current market innovation and gain useful intelligence that can help our requirement. To request the PMEN documents please contact: Name and Email address macy.johnson248@teamleidos.mod.uk In the email request the documents related the Supply and Manufacture of Unlicensed Medicines. The documents will then be sent for completion and should be returned to the same email addresses before the deadline. Responses are required as soon as possible to inform next steps, but the PMEN will remain open until 30/11/2026. The value of this framework is estimated to be between £2,000,000 - £3,000,000

Ostali lijekovi (koji nisu uključeni u kategorije pod rednim brojem 1 i 17) - XXIII - za zdravstvene ustanove u Republici Hrvatskoj

Klinički bolnički centar Zagreb, Grad Zagreb

Ostali lijekovi (koji nisu uključeni u kategorije pod rednim brojem 1. i 17.) - XXII - za zdravstvene ustanove u Republici Hrvatskoj

Klinički bolnički centar Zagreb, Grad Zagreb

ЛЕКОВИ СА Д ЛИСТЕ ЛЕКОВА РФЗО

КЛИНИЧКО-БОЛНИЧКИ ЦЕНТАР "ДР ДРАГИША МИШОВИЋ-ДЕДИЊЕ", БЕОГРАД, ПИБ: 101369025

Лекови ван листе лекова

УНИВЕРЗИТЕТСКИ КЛИНИЧКИ ЦЕНТАР СРБИЈЕ, БЕОГРАД, ПИБ: 100118429

NHS National Framework for Pertuzumab

NHS England

Project title: NHS National Framework for Pertuzumab Offer reference number: CM/TNS/26/5765 Period of framework: 1 August 2027 to 31 August 2028 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Дезинфекциона средства-2

"ИНСТИТУТ ЗА ОНКОЛОГИЈУ ВОЈВОДИНЕ", СРЕМСКА КАМЕНИЦА, ПИБ: 100804613

Набавка Регистрованих лекова ван Листе лекова – фарицимаб и анифролумаб за потребе Универзитетског клиничког центра Војводине

УНИВЕРЗИТЕТСКИ КЛИНИЧКИ ЦЕНТАР ВОЈВОДИНЕ, НОВИ САД, ПИБ: 101696893

Jednogodišnja nabava lijekova - infuzijske otopine

Klinički bolnički centar Zagreb, Grad Zagreb